Literature DB >> 17133780

Nourkrin: objective and subjective effects and tolerability in persons with hair loss.

E Thom1.   

Abstract

This randomized, double-blind, placebo-controlled study was designed to investigate the efficacy and tolerability of Nourkrin, a new natural agent for the treatment of hair loss based on marine proteins, and minerals and vitamins. Fifty-five subjects with hair loss of different aetiologies participated in the 6-month blinded phase of the study. Objective assessments showed a significant positive effect of treatment on hair growth. Intake of the active preparation for a further 6 months in an open phase indicated a subjective further improvement in hair growth. Exposure of the patients previously treated with placebo to the active preparation for 12 months gave similar results. Tolerability was good and no side-effects were reported. Nourkrin may provide an alternative to pharmacotherapy for the treatment of hair-loss problems in individuals with androgenetic alopecia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17133780     DOI: 10.1177/147323000603400508

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

Review 1.  Interventions for female pattern hair loss.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Jan Schoones
Journal:  Cochrane Database Syst Rev       Date:  2016-05-26

Review 2.  Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium.

Authors:  Jan Wadstein; Erling Thom; Aida Gadzhigoroeva
Journal:  Dermatol Res Pract       Date:  2020-05-05

Review 3.  Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis-The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint-A Review.

Authors:  Erik Fink Eriksen; Osvandre Lech; Gilberto Yoshinobu Nakama; Denise M O'Gorman
Journal:  Clin Pract       Date:  2021-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.